¡Ya estamos en !
Descubre más
BCEL
Atreca
Excluida de cotización
BCEL dejó de cotizar en bolsa el 18 de marzo de 2024.
Acerca de: Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Empleados: 90
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
Gráficos de precios implementados con Lightweight Charts™